Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guselkumab in Active Psoriatic Arthritis
NCT02319759Phase 2Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- Mar 2015
- Primary completion
- May 2016
- Modality
- Monoclonal Antibodies
- Countries
- 7
01
Overview
A Phase 2 trial of guselkumab in psoriatic arthritis (PsA), sponsored by Janssen Pharmaceutical. Started Mar 2015; status: completed.
02
Drugs
guselkumab
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NCT02319759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319759.